Verona Pharma plc (NASDAQ:VRNA) CEO Sells $413,292.16 in Stock

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 94,144 shares of Verona Pharma stock in a transaction on Monday, November 4th. The shares were sold at an average price of $4.39, for a total value of $413,292.16. Following the completion of the transaction, the chief executive officer now directly owns 15,204,752 shares of the company’s stock, valued at $66,748,861.28. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

David Zaccardelli also recently made the following trade(s):

• On Friday, November 1st, David Zaccardelli sold 46,888 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $205,369.44.
• On Friday, October 25th, David Zaccardelli sold 4,800 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $21,024.00.
• On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $70.08.
• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $483,797.28.
• On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $1,076,533.92.

Verona Pharma Trading Up 1.6 %

Shares of NASDAQ:VRNA opened at $38.18 on Friday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 8.61 and a current ratio of 13.03. The business has a 50 day moving average of $31.28 and a 200-day moving average of $22.59. Verona Pharma plc has a 12-month low of $11.39 and a 12-month high of $39.40.

Verona Pharma (NASDAQ:VRNA) last announced its earnings results on Monday, November 4th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.12). The company had revenue of $5.62 million for the quarter, compared to analyst estimates of $2.31 million. During the same period in the previous year, the company earned ($0.18) earnings per share. On average, equities analysts predict that Verona Pharma plc will post -2.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on VRNA. Wells Fargo & Company upped their target price on Verona Pharma from $50.00 to $64.00 and gave the company an “overweight” rating in a research report on Tuesday. Canaccord Genuity Group upped their target price on Verona Pharma from $37.00 to $44.00 and gave the company a “buy” rating in a report on Tuesday. Truist Financial upped their price target on Verona Pharma from $38.00 to $44.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Finally, HC Wainwright upped their target price on shares of Verona Pharma from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $43.83.

Hedge Funds Weigh In On Verona Pharma

Several institutional investors have recently added to or reduced their stakes in the stock. First Turn Management LLC purchased a new stake in Verona Pharma during the third quarter valued at about $16,483,000. Claro Advisors LLC bought a new stake in Verona Pharma in the 3rd quarter worth approximately $209,000. GSA Capital Partners LLP purchased a new position in shares of Verona Pharma during the 3rd quarter worth about $849,000. Crossmark Global Holdings Inc. purchased a new stake in Verona Pharma in the third quarter worth $465,000. Finally, Atria Investments Inc bought a new position in shares of Verona Pharma during the third quarter valued at approximately $548,000. Institutional investors own 85.88% of the company’s stock.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.